Skip to main content

REVIEW article

Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1514120
This article is part of the Research Topic Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies Volume II View all 8 articles

Revolutionizing Ovarian Cancer Therapy by Drug Repositioning for Accelerated and Cost-Effective Treatments

Provisionally accepted
Edgar Yebran Villegas-Vazquez Edgar Yebran Villegas-Vazquez 1Francisco Pável Marín-Carrasco Francisco Pável Marín-Carrasco 1Octavio Daniel Reyes-Hernández Octavio Daniel Reyes-Hernández 1Andrea Baez-Gonzalez Andrea Baez-Gonzalez 2Lilia Patricia Bustamante-Montes Lilia Patricia Bustamante-Montes 3Teresita Padilla-Benavides Teresita Padilla-Benavides 2Laura Itzel Quintas-Granados Laura Itzel Quintas-Granados 4*Gabriela Figueroa-González Gabriela Figueroa-González 1*
  • 1 National Autonomous University of Mexico, México City, México, Mexico
  • 2 Wesleyan University, Middletown, Connecticut, United States
  • 3 Centro Universitario Siglo XXI, San Miguel Zinacantepec, Mexico
  • 4 Universidad Autónoma de la Ciudad de México, Mexico City, Mexico

The final, formatted version of the article will be published soon.

    Drug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow. This review focuses on drug repositioning for ovarian cancer treatment, showcasing a comprehensive exploration grounded in thorough in vitro experiments across diverse cancer cell lines, which are validated through preclinical in vivo models. These insights not only shed light on the efficacy of these drugs but also expand in potential synergies with other pharmaceutical agents, favoring the development of costeffective treatments for cancer patients.

    Keywords: Cancer, ovarian cancer, Conventional treatment, Drug Repositioning, Cancer hallmarks

    Received: 20 Oct 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 Villegas-Vazquez, Marín-Carrasco, Reyes-Hernández, Baez-Gonzalez, Bustamante-Montes, Padilla-Benavides, Quintas-Granados and Figueroa-González. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Laura Itzel Quintas-Granados, Universidad Autónoma de la Ciudad de México, Mexico City, Mexico
    Gabriela Figueroa-González, National Autonomous University of Mexico, México City, 04510, México, Mexico

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.